Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (14)

Company Market Cap Price
NVO Novo Nordisk A/S
Prefillable syringe formats for ready-to-administer injections are used for GLP-1 therapies.
$223.06B
$49.45
-1.19%
BDX Becton, Dickinson and Company
BD manufactures prefillable syringes as a core product line for injectable therapies.
$51.22B
$178.68
-0.39%
CAH Cardinal Health, Inc.
Prefillable syringe devices used for ready-to-administer injections.
$45.55B
$190.72
+0.46%
WST West Pharmaceutical Services, Inc.
Prefillable syringe products are a core part of West's High-Value Product (HVP) and delivery systems.
$20.28B
$282.21
+1.32%
ATR AptarGroup, Inc.
Aptar offers ready-to-administer prefilled syringe formats, a key injectable delivery modality.
$7.64B
$115.98
-6.73%
STVN Stevanato Group S.p.A.
Directly manufactures Prefillable Syringes used for sterile biologic and small-molecule injections.
$7.64B
$25.42
+1.92%
ALKS Alkermes plc
Prefillable syringes as a packaging/administration technology for injectable products.
$5.07B
$30.70
-0.39%
AMRX Amneal Pharmaceuticals, Inc.
Prefillable syringes for ready-to-administer injections align with injectable drug delivery formats.
$3.39B
$10.82
+8.20%
XERS Xeris Biopharma Holdings, Inc.
Prefillable Syringes describe a major packaging format used for injectable drugs in Xeris's portfolio.
$1.55B
$9.69
-0.21%
LFCR Lifecore Biomedical, Inc.
New 5-head aseptic isolator filler expands capacity for filling into prefilled syringes.
$266.21M
$7.18
+1.13%
KRMD KORU Medical Systems, Inc.
Prefillable syringes compatible with the Freedom system are a direct product category promoted by KRMD.
$182.72M
$3.94
+1.15%
HRTX Heron Therapeutics, Inc.
ZYNRELEF PFS program indicates Prefillable Syringes as a direct product format.
$176.97M
$1.15
+0.88%
RVP Retractable Technologies, Inc.
Direct product: prefillable syringe devices (0.5mL, 1mL, 3mL variants) included in RVP's portfolio.
$26.28M
$0.86
-1.01%
STSS Sharps Technology, Inc.
Product category: Prefillable syringes (low-waste design) for ready-to-administer injections.
$4.49M
$4.43
-1.56%

Loading company comparison...

Loading research report...

ATR AptarGroup, Inc.

AptarGroup Reports Q3 2025 Earnings: Net Income $127.9 Million, EPS $1.92

Oct 31, 2025
LFCR Lifecore Biomedical, Inc.

Lifecore Biomedical and PolyPeptide Laboratories Announce End‑to‑End Peptide Manufacturing Collaboration

Oct 28, 2025
ALKS Alkermes plc

Alkermes Faces Regulatory Investigation Over Avadel Acquisition

Oct 23, 2025
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Reports Third‑Quarter 2025 Results

Oct 23, 2025
STVN Stevanato Group S.p.A.

Stevanato Group Expands Drug Delivery Capacity in Germany

Oct 21, 2025
ATR AptarGroup, Inc.

Aptar Digital Health Receives FDA 510(k) Clearance for HeroTracker® Sense

Oct 16, 2025
STSS Sharps Technology, Inc.

Sharps Technology Expands Solana Treasury Strategy with Coinbase Partnership

Oct 10, 2025
XERS Xeris Biopharma Holdings, Inc.

New U.S. Patent for Recorlev® Listed in Orange Book, Extending Protection to 2040

Aug 25, 2025
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Files Shelf Registration for Potential Equity Offering

Aug 24, 2025
XERS Xeris Biopharma Holdings, Inc.

Xeris Biopharma Achieves Record Q2 2025 Revenue, Raises Full-Year Guidance to $280-$290 Million

Aug 07, 2025
STVN Stevanato Group S.p.A.

Stevanato Group Reports Strong Q2 2025 Revenue Growth and Expanded Margins, Reaffirms Full-Year Guidance

Aug 05, 2025
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Reports Strong Q2 2025 Results and Significantly Raises Full-Year Guidance

Jul 24, 2025
STVN Stevanato Group S.p.A.

Stevanato Group Secures €200 Million Financing for U.S. and Italian CAPEX Investments

Jul 23, 2025
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Appoints Robert McMahon as New Chief Financial Officer

Jul 21, 2025
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Dropped from Multiple Russell Growth Indices

Jun 30, 2025
XERS Xeris Biopharma Holdings, Inc.

Xeris Biopharma Targets $750 Million Revenue by 2030, Highlights XP-8121's Multi-Billion Dollar Potential

Jun 03, 2025
STVN Stevanato Group S.p.A.

Stevanato Group Shareholders Approve New Board Appointments at Annual Meeting

May 23, 2025
STVN Stevanato Group S.p.A.

Stevanato Group Reports Strong Q1 2025 Results, Maintains Revenue Guidance Despite Tariff Impact

May 08, 2025
XERS Xeris Biopharma Holdings, Inc.

Xeris Biopharma Achieves Record Q1 2025 Revenue and Positive Adjusted EBITDA, Tightens Full-Year Guidance

May 08, 2025
STVN Stevanato Group S.p.A.

Stevanato Group Publishes 2024 ESG Report, Commits to Science-Based Emissions Reductions

Apr 28, 2025
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Announces CFO Retirement and New Chief Proprietary Segment Officer Appointment

Apr 24, 2025
XERS Xeris Biopharma Holdings, Inc.

Xeris Biopharma Strengthens Board with New Director Appointment

Mar 28, 2025
XERS Xeris Biopharma Holdings, Inc.

FDA Approves Xeris' Gvoke VialDx™ for Diagnostic Use

Mar 17, 2025
STVN Stevanato Group S.p.A.

Stevanato Group Reports Record €1.104 Billion Revenue for Fiscal Year 2024, Introduces 2025 Guidance

Mar 06, 2025
XERS Xeris Biopharma Holdings, Inc.

Xeris Biopharma Delivers Record Full-Year 2024 Financial Results and Sets 2025 Revenue Guidance

Mar 06, 2025
XERS Xeris Biopharma Holdings, Inc.

Dr. Anh Nguyen Named Chief Medical Officer at Xeris Biopharma Ahead of XP-8121 Phase 3 Trial

Feb 24, 2025
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Reports Q4 and Full-Year 2024 Results, Issues Disappointing 2025 Guidance

Feb 13, 2025
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Introduces Daikyo PLASCAP® RUV Closures in New Nested Format

Jan 22, 2025
XERS Xeris Biopharma Holdings, Inc.

Xeris Pharmaceuticals Partners with American Diabetes Association for Hypoglycemia Awareness

Jan 21, 2025
XERS Xeris Biopharma Holdings, Inc.

Xeris Biopharma Projects Full-Year 2024 Revenue Exceeding Guidance, Driven by Recorlev

Jan 10, 2025
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Elects Janet Haugen to Board of Directors

Dec 11, 2024
XERS Xeris Biopharma Holdings, Inc.

Xeris Biopharma Reports Record Third Quarter 2024 Revenue and Raises Full-Year Guidance

Nov 08, 2024
STVN Stevanato Group S.p.A.

Stevanato Group Reports Q3 2024 Financial Results Amidst Vial Destocking and Engineering Optimization

Nov 05, 2024
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Services Reports Solid Q3 2024 Results and Raises Full-Year Guidance

Oct 24, 2024

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks